These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26703669)

  • 1. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
    Shtraizent N; Matsui H; Polotskaia A; Bargonetti J
    Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010022. PubMed ID: 26703669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
    Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
    Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
    Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
    Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
    Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
    Polotskaia A; Xiao G; Reynoso K; Martin C; Qiu WG; Hendrickson RC; Bargonetti J
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1220-9. PubMed ID: 25733866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.
    Ellison V; Annor GK; Freedman C; Xiao G; Lundine D; Freulich E; Prives C; Bargonetti J
    Oncotarget; 2021 Jun; 12(12):1128-1146. PubMed ID: 34136083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.
    Xiao G; Annor GK; Fung K; Keinänen O; Zeglis BM; Bargonetti J
    Mol Pharm; 2021 Jan; 18(1):338-346. PubMed ID: 33289569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
    Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
    Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.
    Annor GK; Elshabassy N; Lundine D; Conde DG; Xiao G; Ellison V; Bargonetti J
    Front Cell Dev Biol; 2021; 9():772315. PubMed ID: 34881245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
    Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
    Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Kong Y; Brown ML; Bae I
    Oncotarget; 2013 Jul; 4(7):984-94. PubMed ID: 23846322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
    Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
    Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
    Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
    Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in somatic TP53 mutation type in breast tumors by race and receptor status.
    Pollock NC; Ramroop JR; Hampel H; Troester MA; Conway K; Hu JJ; Freudenheim JL; Olopade OI; Huo D; Ziv E; Neuhausen SL; Stevens P; McElroy JP; Toland AE
    Breast Cancer Res Treat; 2022 Apr; 192(3):639-648. PubMed ID: 35286522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced immortalization, HUWE1 mutations and other biological drivers of breast invasive carcinoma in Black/African American patients.
    Andey T; Attah MM; Akwaaba-Reynolds NA; Cheema S; Parvin-Nejad S; Acquaah-Mensah GK
    Gene; 2020 Dec; 763S():100030. PubMed ID: 34493366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure.
    Shi M; Shtraizent N; Polotskaia A; Bargonetti J; Matsui H
    PLoS One; 2014; 9(6):e99351. PubMed ID: 24937470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
    Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
    J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor.
    Lai ZY; Tsai KY; Chang SJ; Chuang YJ
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Throughput RNA Interference Screen Targeting Synthetic-Lethal Gain-of-Function of Oncogenic Mutant TP53 in Triple-Negative Breast Cancer.
    Rokudai S
    Methods Mol Biol; 2020; 2108():297-303. PubMed ID: 31939190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct Classes of Flavonoids and Epigallocatechin Gallate, Polyphenol Affects an Oncogenic Mutant p53 Protein, Cell Growth and Invasion in a TNBC Breast Cancer Cell Line.
    Kollareddy M; Martinez LA
    Cells; 2021 Apr; 10(4):. PubMed ID: 33918387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.